FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, today announced the pricing of its underwritten registered public offering of 6,666,667 shares of its common stock, offered at a price to the public of $3.00 per share for expected gross proceeds of $20.0 million, before deducting underwriting discounts and commission
03:55
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia 2019 AGM Results
02:00
CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure Announces Preclinical Data Supporting Development of SNA Technology in the Central Nervous System
01:12
KENILWORTH, N.J.--(BUSINESS WIRE)--<a href="https://twitter.com/search?q=%24MRK&src=ctag" target="_blank">$MRK</a> <a href="https://twitter.com/hashtag/MRK?src=hash" target="_blank">#MRK</a>--CDC's ACIP Votes to Provisionally Recommend Shared Clinical Decision-Making for Vaccination of Adults Ages 27-45 with GARDASIL9
Wed Jun 26, 2019 23:45
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, today announced that it has commenced an underwritten public offering of its common stock. All of the shares to be sold in the offering are to be sold by Motus GI. In connection with the offering, Motus GI intends to grant the underwriters a 30-day option to purchase
Wed Jun 26, 2019 23:01
ROSEVILLE, Minn.--(BUSINESS WIRE)--<a href="https://twitter.com/hashtag/Cdiff?src=hash" target="_blank">#Cdiff</a>--Members of the Rebiotix senior leadership team to engage in key panel discussions at the Microbiome Movement-Drug Development Summit
Wed Jun 26, 2019 21:13
STONY BROOK, N.Y.--(BUSINESS WIRE)--<a href="https://twitter.com/search?q=%24apdn&src=ctag" target="_blank">$apdn</a> <a href="https://twitter.com/hashtag/alzheimers?src=hash" target="_blank">#alzheimers</a>--LineaRx, Inc. a wholly-owned subsidiary of Applied DNA Sciences, Inc. (NASDAQ: APDN), announced today that it has shipped multiple customized linear DNA amplicons to Evotec SE, a well-known therapeutic development company, to support their research efforts related...
Wed Jun 26, 2019 16:15
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics announced today that Dr. Mihály Hajós, has been appointed Chief Scientific Officer.
Wed Jun 26, 2019 16:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--X4 Pharmaceuticals, Inc. (Nasdaq:XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the initiation of 4WHIM, a pivotal Phase 3 global clinical trial of mavorixafor (X4P-001) for the treatment of WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare, inherited, primary immunodeficiency disease. The global 4WHIM trial is a 52-week, ra
Wed Jun 26, 2019 15:30
BURLINGTON, Mass. & OXFORD, UK--(BUSINESS WIRE)--Blue Earth Diagnostics, a molecular imaging diagnostics company, today announced results from early clinical experience in Germany with positron emission tomography (PET) (PET/CT or PET/MRI) imaging using a radiohybrid Prostate Specific Membrane Antigen-targeted compound (18F-rhPSMA-7). The presentations were made by the Technical University of Munich (TUM) and Ludwig-Maximilian-University (LMU), Munich. Blue Earth Diagnostics acquired exclusive
Wed Jun 26, 2019 15:30
BURLINGTON, Mass. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a molecular imaging diagnostics company, today announced results from a retrospective, observational analysis evaluating the safety and effectiveness of 18F-fluciclovine in the detection of recurrent gliomas in adults, using data from multiple research sites. The primary aim was to determine the Positive Predictive Value (PPV) of 18F-fluciclovine PET to detect glioma in comparison to a histopathological truth standard
Wed Jun 26, 2019 15:15
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein Medical Enhances Telemedicine Solution With Medpod MobileDoc 2
Wed Jun 26, 2019 15:04
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today it has completed target enrollment of patients with pulmonary arterial hypertension (PAH) in the PULSAR Phase 2 trial of sotatercept. The Company now expects to report top-line results during the first quarter of 2020. “We’re thrilled with PULSAR’s rapid enrollment ove
Wed Jun 26, 2019 14:35
ST. HELIER, Jersey--(BUSINESS WIRE)--The German Institute for Quality and Efficiency in Healthcare has published its rapid report noting Optune’s survival benefit in newly diagnosed GBM.
Wed Jun 26, 2019 14:30
PLEASANTON, Calif.--(BUSINESS WIRE)--<a href="https://twitter.com/hashtag/activeTMF?src=hash" target="_blank">#activeTMF</a>--Celltrion, a top South Korean biopharmaceutical company, implemented Veeva Vault eTMF to improve visibility and compliance across TMF processes.
Wed Jun 26, 2019 14:03
CAMBRIDGE, Mass. & HAIFA, Israel--(BUSINESS WIRE)--Minovia Announces Dosing of Patient in First Mitochondrial Cell Therapy Trial for the Treatment of Pearson Syndrome
Wed Jun 26, 2019 14:00
PLANO, Texas--(BUSINESS WIRE)--Infinix Global Meetings & Events to Acquire MIM, Meetings & Events
Wed Jun 26, 2019 14:00
DUBLIN--(BUSINESS WIRE)--The "Pyrogen Testing Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering. The market is primarily driven by increased demand for pyrogen testing products in the pharmaceutical and biotechnology industry and rising investments in research and development. The presence of well-developed healthcare infrastructure, well-defined rules, and regulations for pharmaceutical manufacturing process should help North Americ
Wed Jun 26, 2019 13:38
新加坡--(BUSINESS WIRE)--(美国商业资讯)--全球领先的信息安全会议和展览RSA Conference (RSAC)今天宣布了将参加RSAC 2019 APJ的RSAC Launch Pad计划的前三名入围者。RSAC Launch Pad是RSAC为该地区快速发展的早期和成长阶段网络安全初创公司生态系统提供的主要创新计划之一。在7月17日（周三），这些入围者将向由两位成功的风险资本家(VC)和一位首席信息安全官(CISO)组成的小组推销他们的网络安全创新，以获取将他们的业务提升到下一个水平的机会。 为了加速数字化转型和协作，并帮助保护不断扩大的区域威胁形势，RSAC致力于为创新理念提供平台以帮助抵御不断演变的新型威胁，并将这些想法推荐给更广泛的网络安全社区。 RSAC Launch Pad入围者（按字母顺序排列）是： Cydarm：Cydarm通过其案例管理系统重振组织的事件响应计划。通过对广泛协作需求的深入了解以及与安全运营中心(SOC)之外的利益相关者的快速沟通，该公司帮助组织在其事件响应能力范围内实施最佳实践。 SecureStack：SecureStack
Wed Jun 26, 2019 13:30
新加坡--(BUSINESS WIRE)--(美國商業資訊)--全球首屈一指的資訊安全會議和展覽RSA Conference (RSAC)今天宣佈將參加RSAC 2019 APJ的RSAC Launch Pad計畫的前三名入圍者。RSAC Launch Pad是RSAC為該地區快速成長的早期和成長階段網路安全初創公司生態系統提供的主要創新計畫之一。在7月17日（週三），這些入圍者將向由兩位成功的創投資本家(VC)和一位資訊安全長(CISO)組成的小組推銷他們的網路安全創新，以獲得將他們的業務提升到下一個層級的機會。 為了加速數位轉型和合作，並協助保護不斷擴大的區域威脅形勢，RSAC致力於為創新理念提供平臺以幫助抵禦不斷演變的新型威脅，並將這些想法推薦給更廣泛的網路安全社群。 RSAC Launch Pad入圍者（按字母順序排列）是： Cydarm：Cydarm透過其案例管理系統重振組織的事件回應計畫。憑藉對廣泛合作需求的深入瞭解，以及與資安監控中心(SOC)之外的利害關係者的快速溝通，該公司協助組織在其事件回應能力範圍內實施最佳實務。 SecureStack：SecureStack為
Wed Jun 26, 2019 13:30
シンガポール--(BUSINESS WIRE)--（ビジネスワイヤ） -- 情報セキュリティーに関する世界有数の会議・展示会であるRSAカンファレンス（RSAC）は本日、RSAC 2019 APJでRSACローンチ・パッドの最終候補企業3社を発表しました。RSACローンチ・パッドは、アジア太平洋地域の初期ステージ、成長ステージにあるサイバーセキュリティー新興企業にRSACが提供する主要イノベーション・プログラムの1つです。最終候補企業は7月17日水曜日に、著名ベンチャーキャピタリスト（VC）2名と最高情報セキュリティー責任者（CISO）1名で構成される審査員団を前に自社のサイバーセキュリティー・イノベーションについてプレゼンテーションを行い、ビジネスを次の段階に進めるチャンスの獲得を目指します。 RSACは、デジタル化による変革とコラボレーションを促進し、この地域で拡大しているセキュリティー脅威に対する防御に寄与すべく、進化する新しい脅威に対抗する革新的アイデアのためのプラットフォームを提供し、そうしたアイデアを広範なサイバーセキュリティー・コミュニティーに紹介することに努力していま
Wed Jun 26, 2019 13:30
MONTPELLIER, France--(BUSINESS WIRE)--The "AUDINNOVE" project led by AP-HP in partnership with Institut Pasteur, “la Fondation pour l’Audition” and Sensorion will receive a € 9.7m grant
Wed Jun 26, 2019 08:30
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου